Mutations in gp41 and gp120 of HIV-1 isolates resistant to hexa-arginine neomycin B conjugate

Biochemical and Biophysical Research Communications

Volumn 312, Issue 4, 2003, Pages 1047-1052

  Borkow, Gadi ^a,b   Lara, Humberto Herman ^a,c   Lapidot, Aviva ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

Author keywords

Aminoglycoside arginine conjugates; Gp120; Gp41; Heptad repeat; HIV 1; Mutations; Viral entry

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; ARGININE DERIVATIVE; CD4 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; FRAMYCETIN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; TRANSACTIVATOR PROTEIN; VIRUS GLYCOPROTEIN;

ARTICLE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG POTENCY; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; VIRUS ISOLATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0344926359     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2003.11.011     Document Type: Article

References (45)

1. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., Hendrickson W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature. 393:1998;648-659.
2. Zhang W., Canziani G., Plugariu C., Wyatt R., Sodroski J., Sweet R., Kwong P., Hendrickson W., Chaiken I. Conformational changes of gp120 in epitopes near the CCR5 binding site are induced by CD4 and a CD4 miniprotein mimetic. Biochemistry. 38:1999;9405-9416.
3. Berger E.A., Murphy P.M., Farber J.M. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17:1999;657-700.
4. Cammack N. Human immunodeficiency virus type 1 entry and chemokine receptors: a new therapeutic target. Antivir. Chem. Chemother. 10:1999;53-62.
5. Choe H., Martin K.A., Farzan M., Sodroski J., Gerard N.P., Gerard C. Structural interactions between chemokine receptors, gp120 Env and CD4. Semin. Immunol. 10:1998;249-257.
6. Clapham P.R., McKnight A. HIV-1 receptors and cell tropism. Br. Med. Bull. 58:2001;43-59.
7. Zaitseva M., Peden K., Golding H. HIV coreceptors: role of structure, posttranslational modifications, and internalization in viral-cell fusion and as targets for entry inhibitors. Biochim. Biophys. Acta. 1614:2003;51-61.
8. Wu L., Gerard N.P., Wyatt R., Choe H., Parolin C., Ruffing N., Borsetti A., Cardoso A.A., Desjardin E., Newman W., Gerard C., Sodroski J. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature. 384:1996;179-183.
9. Shioda T., Levy J.A., Cheng-Mayer C. Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene. Nature. 349:1991;167-169.
10. Shioda T., Levy J.A., Cheng-Mayer C. Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA. 89:1992;9434-9438.
11. Hwang S.S., Boyle T.J., Lyerly H.K., Cullen B.R. Identification of envelope V3 loop as the major determinant of CD4 neutralization sensitivity of HIV-1. Science. 257:1992;535-537.
12. Hoffman T.L., Doms R.W. HIV-1 envelope determinants for cell tropism and chemokine receptor use. Mol. Membr. Biol. 16:1999;57-65.
13. Cocchi F., Devico A.L., Garzino-Demo A., Cara A., Gallo R.C., Lusso P. The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nat. Med. 2:1996;1244-1247.
14. Cheng-Mayer C., Shioda T., Levy J.A. Host range, replicative, and cytopathic properties of human immunodeficiency virus type 1 are determined by very few amino acid changes in tat and gp120. J. Virol. 65:1991;6931-6941.
15. Mondor I., Moulard M., Ugolini S., Klasse P.J., Hoxie J., Amara A., Delaunay T., Wyatt R., Sodroski J., Sattentau Q.J. Interactions among HIV gp120, CD4, and CXCR4: dependence on CD4 expression level, gp120 viral origin, conservation of the gp120. Virology. 248:1998;394-405.
16. Trkola A., Dragic T., Arthos J., Binley J.M., Olson W.C., Allaway G.P., Cheng-Mayer C., Robinson J., Maddon P.J., Moore J.P. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature. 384:1996;184-187.
17. Rizzuto C.D., Wyatt R., Hernandez-Ramos N., Sun Y., Kwong P.D., Hendrickson W.A., Sodroski J. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science. 280:1998;1949-1953.
18. Weissenhorn W., Dessen A., Harrison S.C., Skehel J.J., Wiley D.C. Atomic structure of the ectodomain from HIV-1 gp41. Nature. 387:1997;426-430.
19. Tan K., Liu J., Wang J., Shen S., Lu M. Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc. Natl. Acad. Sci. USA. 94:1997;12303-12308.
20. Chan D.C., Fass D., Berger J.M., Kim P.S. Core structure of gp41 from the HIV envelope glycoprotein. Cell. 89:1997;263-273.
21. Doms R.W., Moore J.P. HIV-1 membrane fusion: targets of opportunity. J. Cell Biol. 151:2000;F9-F14.
22. Moore J.P., Doms R.W. The entry of entry inhibitors: a fusion of science and medicine. Proc. Natl. Acad. Sci. USA. 100:2003;10598-10602.
23. Moore J.P., Stevenson M. New targets for inhibitors of HIV-1 replication. Nat. Rev. Mol. Cell Biol. 1:2000;40-49.
24. O'Hara B.M., Olson W.C. HIV entry inhibitors in clinical development. Curr. Opin. Pharmacol. 2:2002;523-528.
25. De Clercq E. New anti-HIV agents and targets. Med. Res. Rev. 22:2002;531-565.
26. De Clercq E. The emerging role of fusion inhibitors in HIV infection. Drugs R D. 2:1999;321-331.
27. Este J.A. Virus entry as a target for anti-HIV intervention. Curr. Med. Chem. 10:2003;1617-1632.
28. Baldwin C.E., Sanders R.W., Berkhout B. Inhibiting HIV-1 entry with fusion inhibitors. Curr. Med. Chem. 10:2003;1633-1642.
29. Duffalo M.L., James C.W. Enfuvirtide: a novel agent for the treatment of HIV-1 infection. Ann. Pharmacother. 37:2003;1448-1456.
30. Labrosse B., Labernardiere J.L., Dam E., Trouplin V., Skrabal K., Clavel F., Mammano F. Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors. J. Virol. 77:2003;1610-1613.
31. Lapidot A., Litovchick A. Novel HIV Tat antagonists. Drug Dev. Res. 50:2001;502-515.
32. Litovchick A., Evdokimov A.G., Lapidot A. Aminoglycoside-arginine conjugates that bind TAR RNA: synthesis, characterization, and antiviral activity. Biochemistry. 39:2000;2838-2852.
33. Litovchick A., Evdokimov A.G., Lapidot A. Arginine-aminoglycoside conjugates that bind to HIV transactivation responsive element RNA in vitro. FEBS Lett. 445:1999;73-79.
34. Litovchick A., Lapidot A., Eisenstein M., Kalinkovich A., Borkow G. Neomycin B-arginine conjugate, a novel HIV-1 Tat antagonist: synthesis and anti-HIV activities. Biochemistry. 40:2001;15612-15623.
35. G. Borkow, V. Vijayabaskar, H.H. Lara, A. Kalinkovich, A. Lapidot, Structure-activity relationship of neomycin, paromomycin, and neamine-argine conjugates, targeting HIV-1 gp120-CXCR4 binding step, Antiviral Res. (2003), in press.
36. Cabrera C., Gutierrez A., Blanco J., Barretina J., Litovchick A., Lapidot A., Evdokimov A.G., Clotet B., Este J.A. Anti-human immunodeficiency virus activity of novel aminoglycoside- arginine conjugates at early stages of infection. AIDS Res. Hum. Retroviruses. 16:2000;627-634.
37. Cabrera C., Gutierrez A., Barretina J., Blanco J., Litovchick A., Lapidot A., Clotet B., Este J.A. Anti-HIV activity of a novel aminoglycoside-arginine conjugate. Antiviral Res. 53:2002;1-8.
38. Catani M.V., Corasaniti M.T., Litovchick A., Lapidot A., Melino G. The Tat antagonist NeoR inhibits gp120-induced death of human neuroblastoma cells. J. Neurochem. 8:2003;1237-1245.
39. Chackerian B., Long E.M., Luciw P.A., Overbaugh J. Human immunodeficiency virus type 1 coreceptors participate in postentry stages in the virus replication cycle and function in simian immunodeficiency virus infection. J. Virol. 71:1997;3932-3939.
40. Collins K.B., Patterson B.K., Naus G.J., Landers D.V., Gupta P. Development of an in vitro organ culture model to study transmission of HIV-1 in the female genital tract. Nat. Med. 6:2000;475-479.
41. Sambrook J., Fritsch E.F., Maniatis T. Molecular Cloning: a Laboratory Manual. second ed. 1989;Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
42. Carriere M., Vijayabaskar V., Applefield D., Harvey I., Garneau P., Lorsch J., Lapidot A., Pelletier J. Inhibition of protein synthesis by aminoglycoside-arginine conjugates. RNA. 8:2002;1267-1279.
43. Ennifar E., Paillart J.C., Marquet R., Ehresmann B., Ehresmann C., Dumas P., Walter P. HIV-1 RNA dimerization initiation site is structurally similar to the ribosomal A site and binds aminoglycoside antibiotics. J. Biol. Chem. 278:2003;2723-2730.
44. de Vreese K., Kofler-Mongold V., Leutgeb C., Weber V., Vermeire K., Schacht S., Anne J., De Clercq E., Datema R., Werner G. The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication. J. Virol. 70:1996;689-696.
45. Schols D., Este J.A., Cabrera C., De Clercq E. T-cell-line-tropic human immunodeficiency virus type 1 that is made resistant to stromal cell-derived factor 1alpha contains mutations in the envelope gp120 but does not show a switch in coreceptor use. J. Virol. 72:1998;4032-4037.